Trial of Prasinezumab in Early-Stage Parkinson’s Disease - Pagano, Gennaro; Taylor, Kirsten I.; Anzures-Cabrera, Judith; Marchesi, Maddalena; Simuni, Tanya; Marek, Kenneth; Postuma, Ronald B.; Pavese, Nicola; Stocchi, Fabrizio; Azulay, Jean-Philippe; Mollenhauer, Brit; López-Manzanares, Lydia; et al. (The New England journal of medicine, 2022)
Keywords: Activities of daily living; Aging; Aging General; alpha-Synuclein - antagonists & inhibitors; Antibodies, Monoclonal, Humanized - therapeutic use; Antiparkinson Agents - therapeutic use; Clinical outcomes; Computed tomography; Dopamine; Dopamine Plasma Membrane Transport Proteins - therapeutic use; Dopamine transporter; Double-Blind Method; Geriatrics; Humans; Intravenous administration; Monoclonal antibodies; Movement disorders; Neurodegenerative diseases; Neurology; Neurosurgery; Parkinson Disease; Parkinson Disease - drug therapy; Parkinson's disease; Pathogenesis; Placebos; Putamen; Single photon emission computed tomography; Synuclein; Treatment Outcome